Velcera Announces Completion of Enrollment in VEL502 Clinical Trial  
6/9/2008 10:57:41 AM

YARDLEY, PA--(Marketwire - June 09, 2008) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today completion of patient enrollment for its confirmatory clinical study utilizing VEL502 via Promistâ„¢ delivery as a treatment for management of pruritus (itching) associated with allergic dermatitis in dogs. Canine allergic dermatitis is one of the most commonly occurring canine skin diseases, which irritates the skin causing the pet to scratch. VEL502 is Velcera's second product in development based on its patented Promist drug delivery system, which provides a fine liquid mist inside the oral cavity for systemic absorption, avoiding the need for pets to swallow tablets or liquids.